Genentech, Inc. http://www.alacrastore.com/company-snapshot/Genentech_Inc-1006884 08 Nov 2009 04:14:16 EST 1006884 Genentech, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/moodys/PR_182582_600035606PR_182582_600035606moodys/PR_182582_600035606html07 Jul 2009 05:01:01 ESThtmlRoche Holding AGGenentech, Inc.Roche Holdings Inc.Genentech, Inc.; Roche Holding AG; Roche Holdings Inc.60003560631335016530150.000006 Jul 2009NewsRating ActionCGlobal Credit Research Rating Action # JUL #### Rating Action: Roche Holding AG Moody's withdraws ratings of Genentech Approximately $# billion of long term debt affected New York, July ##, #### -- Moody's Investors Service withdrew...Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/bir/303772303772bir/303772norm16Genentech Inc.United States16 Jun 2009 06:13:00 ESTSan Francisco-based Genentech Inc. was founded 30 years ago, in 1976, by the late venture capitalist Robert A. Swanson and the biochemist Dr. Herbert W. Boyer. The company went public in 1980 and had one of the highest stock run-ups in history. Genentech325412M2834I32541454171028368731San Francisco-based Genentech Inc. was founded 30 years ago, in 1976, by the late venture capitalist Robert A. Swanson and the biochemist Dr. Herbert W. Boyer. The company went public in 1980 and had one of the highest stock run-ups in history. GenentechCompany Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/moodys/CMT_0000473316moodys/CMT_0000473316htmlCMT_0000473316Global Credit Research Issuer Comment # FEB #### Issuer Comment: Genentech, Inc. Moody's Covenant Office comments on the covenant protections in the indenture governing Genentech's outstanding bonds in relation to a possible Roche...03 Feb 2009 12:59:42 ESThtmlGenentech, Inc.Genentech, Inc.313350150.0000NewsIssuer CommentCredit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/T2077250ccbn/T2077250norm... - Genentech, Inc. - Chairman, CEO That's for the webcast, apparently. Thank you. We are happy to take -- I won't say any questions -- but most questions. ... 22 Jan 2009 05:05:00 ESTGenentech, Inc.54.0000FinalGenentech, Inc. at JPMorgan Healthcare Conference Q&A Session TranscriptDNA3:00pm PTTranscriptCredit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/moodys/CMT_0000471052moodys/CMT_0000471052htmlGlobal Credit Research Issuer Comment ## JAN #### Issuer Comment: Genentech, Inc. Moody's comments on Genentech's #Q## and ongoing rating review Moody's Investors Service commented that the fourth quarter #### earnings release of Genentech,...17 Jan 2009 01:00:41 ESThtmlGenentech, Inc.Genentech, Inc.313350150.0000NewsIssuer CommentCMT_0000471052Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/T2058040ccbn/T2058040norm...Good afternoon. My name is Christian, and I will be your conference operator today. At this time, I would like to welcome everyone to the Genentech's fourth quarter and year-end #### earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator Instructions). I would now like to turn the conference over to Ms. Kathee Littrell, Vice President of Investor Relations. ... 15 Jan 2009 10:04:00 ESTGenentech, Inc.54.0000FinalGenentech, Inc. Q4 2008 Earnings Conference Call TranscriptDNA1:45pm PTTranscriptCredit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B2058040ccbn/B2058040norm...Reported eight positive phase III clinical trials, including two for Avastin in metastatic breast cancer; initiated more than ## clinical trials. ... 15 Jan 2009 09:04:00 ESTGenentech, Inc.54.0000EditedGenentech, Inc. Q4 2008 Earnings Conference Call SummaryDNA1:45pm PTBriefCredit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2066329ccbn/T2066329norm... - JPMorgan - AnalystGood afternoon. Welcome to the afternoon sessions of the ##th Annual JPMorgan Healthcare Conference. I'm Geoff Meacham, senior biotechnology analyst here at Genentech -- at JPMorgan. And I can think of well, well more than ## reasons why -- or contributions that Genentech has made to medicine, but suffice it to say they are the bellwether of the group and they are the global leader in oncology with key drugs Avastin, Herceptin, and Rituxan. And speaking on behalf of Genentech is its CEO, Dr. Levinson.... 13 Jan 2009 11:07:00 ESTGenentech, Inc.54.0000FinalGenentech, Inc. at JPMorgan Healthcare Conference TranscriptDNA2:30pm PTTranscriptCredit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2021209ccbn/T2021209norm... - Piper Jaffray - AnalystThanks to everybody who is joining us for day number two of the Piper Jaffray healthcare conference. My name is Thomas Wei; I'm one of the senior biotech analysts on the research team at Piper Jaffray. And it's my pleasure to introduce our next presenting company, Genentech. Here to present on behalf of the Company are Kathee Littrell from Investor Relations and Steve Kelsey, the Vice President of Clinical Hematology and Oncology. I do have to point out some very important disclosures that are posted to the right of the room here, and I will pass it over to Steve and Kathee for a brief introduction of Genentech before we open it up to Q&A. ... 03 Dec 2008 02:05:00 ESTGenentech, Inc.54.0000FinalGenentech, Inc. at Piper Jaffray Healthcare Conference TranscriptDNA8:30am ETTranscriptT2021209Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2026436ccbn/T2026436norm... - Lazard Capital Markets - AnalystThanks, everyone, for joining us here at the Genentech presentation. I am Joel Sendek, biotech analyst at Lazard Capital Markets. It is our pleasure to have representatives from Genentech today. And we have two. Kicking off will be Sue Morris, the Director of Investor Relations and subsequent to her discussion, we are very excited to have Dr. Robert Cohen who is a senior oncology fellow and also in the business development division of Genentech. So Bob will follow Sue after her talk. Sue? Oh, and we are going to have time for, I think depending how quickly things go, a few questions at the end. ... 19 Nov 2008 10:05:00 ESTGenentech, Inc.54.0000FinalGenentech, Inc. at Lazard Capital Markets Healthcare Conference TranscriptDNA10:55am ETTranscriptT2026436Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/22184srp/22184norm22184...(#) Percentages are based upon the number of eligible and active companies in the SharkRepellent.net database. For the Poison Pill In Force calculation by index, non-US companies are included. (#) Supermajority vote requirement (e.g., ##.##%, ##%, ##%) for shareholders to amend/repeal at least one charter or bylaw provision. (#) SIC Group is defined as the first two digits of this company's primary SIC code (##: Chemicals And Allied Products). There are ### eligible and active companies in the SharkRepellent.net database in this SIC group. (#) The TrueCourse Bullet Proof Rating is a weighted average index comprised of significant components that impact takeover defenses. The rating scale is from # to ## with a ## representing the most formidable defenses. The rating system is a relative measurement and is not intended to measure the probability of a successful www.SharkRepellent.net... 2218436871040606 Oct 2006 12:16:00 ESTDNACredit & Investment ResearchSharkRepellent.net